In the phase III OLYMPIA 1 trial, Nemolizumab as a monotherapy has significantly improved itch and skin lesions in adult patients with moderate to severe prurigo nodularis, compared to placebo.

Patients treated with Nemolizumab without background topical corticosteroids or topical calcineurin inhibitors, have shown clinically and statistically significant improvements in both primary endpoints, compared to placebo after 16 weeks of treatment, providing independent confirmation of results from the phase III OLYMPIA 2 trial:

58.4% of Nemolizumab-treated patients have achieved an at least four-point reduction in itch, as measured by the PP-NRS score, compared to 16.7% in the placebo group ( p less than 0.0001 );

26.3% of Nemolizumab-treated patients reached clearance or almost-clearance of skin lesions, when assessed using the IGA score, compared to 7.3% in the placebo group ( p less than 0.0001 ).

The trial also met all key secondary endpoints confirming rapid onset of action on itch as early as week 4 ( 41.1% compared to 6.3% in the placebo group; p less than 0.0001 ), and improvements in itch and skin lesions were observed up to week 24.

Nemolizumab was well tolerated, and its safety profile was consistent with OLYMPIA 2 trial results.

These phase III data have demonstrated that Nemolizumab significantly and quickly improves three of the most burdensome symptoms of this condition: itch, skin lesions, and sleep disturbance.

Nemolizumab is a monoclonal antibody specifically designed to target the IL-31 receptor and inhibit IL-31 signaling.
IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis. ( Xagena )

Source: European Academy of Dermatology and Venereology ( EADV ) Congress, 2023

Xagena_Medicine_2023